An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer ...

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting ...

A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting ...

Johnson & Johnson (J&J) said that an early-stage trial of JNJ-6143 (previously HLD-0915) found that the novel oral Regulated ...

Scientists have discovered vital clues to help predict, more than a decade in advance, which men may develop prostate cancer.

Prostate cancer surgery removes the prostate, but for men with high-risk disease, it doesn't always end the story. Cancer can return, spread, or require additional treatment. Researchers are looking ...

In the first-in-human TheraPb phase 1 trial, the alpha-emitting radiopharmaceutical 212Pb-ADVC001 was well tolerated at doses ...

Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to ...

A phase 3 PROTEUS substudy published in European Urology reports that perioperative apalutamide plus hormone therapy around ...

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted ...

New substudy results showed a 51% lower estimated risk of metastasis or death over time with perioperative apalutamide plus ...

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs i ...